Isthmus Partners’s iRadimed IRMD Stock Holding History

Isthmus Partners’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.47M	Sell	25,693 -24,918	-49%	-$2.49M	0.26%	101
2025 Q4	$4.92M	Sell	50,611 -8,129	-14%	-$697K	0.55%	49
2025 Q3	$4.18M	Buy	58,740 +1,396	+2%	+$93K	0.93%	29
2025 Q2	$3.43M	Sell	57,344 -456	-0.8%	-$25K	0.4%	67
2025 Q1	$3.03M	Buy	57,800 +23	+0%	+$1.29K	0.38%	67
2024 Q4	$3.18M	Sell	57,777 -41	-0.1%	-$2.16K	0.39%	68
2024 Q3	$2.91M	Sell	57,818 -14,846	-20%	-$685K	0.35%	80
2024 Q2	$3.19M	Buy	72,664 +759	+1%	+$32.3K	0.38%	79
2024 Q1	$3.16M	Buy	71,905 +64,574	+881%	+$2.85M	0.36%	83
2023 Q4	$348K	Buy	+7,331	New	+$308K	0.05%	150
2023 Q3	–	Sell	-9,937	Closed	-$474K	–	173
2023 Q2	$474K	Sell	9,937 -31	-0.3%	-$1.4K	0.06%	134
2023 Q1	$392K	Buy	+9,968	New	+$362K	0.06%	139

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Isthmus Partners's IRMD Position: Q1 2026 in Review

Isthmus Partners reduced its iRadimed (IRMD) stake by 49% in Q1 2026, selling an estimated $2.49M and leaving 25,693 shares worth $2.47M. The position accounts for 0.26% of the portfolio, ranked #101.

Isthmus Partners first reported a position in IRMD in Q1 2023 and has held it in 12 quarters since. The position peaked at $4.92M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Isthmus Partners held 25,693 shares of iRadimed worth $2.47M as of Q1 2026.
Isthmus Partners sold 24,918 iRadimed shares in Q1 2026, an estimated $2.49M.
iRadimed made up 0.26% of Isthmus Partners's portfolio in Q1 2026, its #101 holding.
Isthmus Partners first reported a position in iRadimed in Q1 2023 and has held it in 12 quarters since.
Isthmus Partners's iRadimed position peaked at $4.92M in Q4 2025.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Isthmus Partners's 13F filing for Q1 2026, filed 30 Apr 2026.